UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19

UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19

Just published in the peer-reviewed American Journal of Therapeutics, Dr. Tess Lawrie, an expert in medicinal evidence, along with other experts in population health and gastroenterology out of the United Kingdom (UK), conducted a comprehensive meta-analysis involving the certainty of evidence using an approach known as GRADE, which led to the focus on twenty-four ivermectin-centered randomized controlled trials involving 3,406 participants. The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result, posits Dr. Lawrie and team, confirmed via trial sequential analysis employing what was the same DerSimonian-Laird method behind the unadjusted analysis. The authors also ran their findings against a trial sequential analysis employing the Biggerstaff-Tweedie method. They found low-certainty evidence that ivermectin prophylaxis (as a preventive method) actually lowered infection association with SARS-CoV-2, the virus behind COVID-19, by an average of 86% (95% CI 79-91%). Also, the team’s findings reveal that the evidence for secondary outcomes, such as efficacy associated with “need for mechanical ventilation” is less compelling; however, effective estimates for “improvement” and “deterioration” point to the positive impact of ivermectin use. The authors found little safety risk as reports of severe adverse events were rare among the reviewed studies.

This study published in the peer-reviewed American Journal of Therapeutics suggests a “moderate-certainty evidence” indicating a substantial reduction in COVID-19 related deaths would be a feasible outcome with the use of ivermectin.  The study results mirror what TrialSite’s observed in study after study from Bangladesh and India to Peru and Argentina; from Israel and Nigeria to the ICON study in South Florida and population-wide public health initiatives using ivermectin from Mexico City to Uttar Pradesh, India, that there’s now overwhelming data that this generic drug used as an antiparasitic treatment should be considered on at least an emergency basis as another tool in the medical tool chest to fight SARS-CoV-2.

Dr. Lawrie shared with the TrialSite:

We are overjoyed to have the product of months of hard work finally published! And what a wonderful author team – it’s been an honour to work with people of such high integrity, who maintained a spirit of hope and optimism in spite of all the difficulties with which we have been confronted.  Thank you for not giving up! Now the authorities have all the evidence they need to approve ivermectin immediately.”

The preprint of this review received no funding. This updated version was funded by the crowdfunding initiative

TrialSite’s Coverage of Ivermectin

TrialSite’s been one of the few, if not the only, media platforms to consistently chronicle ivermectin-based research since the initial findings of a group of scientists last April at Monash University that the generic drug absolutely destroys the SARS-CoV-2 pathogen in a lab setting. TrialSite chronicled the organization, conduct, and conclusion of dozens of studies since then. The platform’s only been rivaled by the anonymously owned platform that tracks every ivermectin study, now at 60. One of the key authors here, Dr. Tess Lawrie, has been a guest on the TrialSite podcast and is a frequent contributor.

Lead Research/Investigator

  • Andrew Bryant, MSc, Division of Gastroenterology, Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom
  • Theresa A. Lawrie, MBBCh, PhD, Division of Gastroenterology, Evidence-based Medicine Consultancy, Bath, United Kingdom
  • Therese Dowswell, PhD, Division of Gastroenterology, Evidence-based Medicine Consultancy, Bath, United Kingdom
  • Edmund J. Fordham, PhD, Division of Gastroenterology, Evidence-based Medicine Consultancy, Bath, United Kingdom
  • Scott Mitchell, MBChB, MRCS, Emergency Department, Princess Elizabeth Hospital, Guernsey, United Kingdom
  • Sarah R. Hill, PhD, Division of Gastroenterology, Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom
  • Tony C. Tham, MD, FRCP, Division of Gastroenterology, Ulster Hospital, Dundonald, Belfast, Northern Ireland, United Kingdom

Call to Action: Perhaps health regulators and apex research institutes can revisit their assessment of this drug. Note the corresponding author is Andrew Bryant who can be reached at [email protected]

Responses

  1. I would like to know how I could get a copy of Tess’ report on the numbers of people injured by the three vaccines.. especially her comment on “It is not known yet, how this “gene therapy” will manifest in years to come… or down the road.. She stated it as if this is not a speculation but an assurance that people who took the JAB will eventually (time not Known & insufficient data).. come down with a health condition as a result of the JAB… What are your plans to counteract this situation with yourself, and your three daughters. I am sad that this will be the case for millions who have taken the JAB.. The Author of this report you mentioned her name as Tess also stated that as a humanitarian effort seeking ways to help people who have been adversely affected soon after the JAB and those down the road who will eventually succumb to health conditions due to the JAB should receive aid… Thank you for your integrity.. although you have taken the JAB and promoted it to your children YOU have come out and honestly stated based on your Ethical investigations that to keep moving forward with the Covid injection agenda without further and thorough study is WRONG and needs to stop . THANK YOU for that…

  2. Thank you TrialSiteNews for your coverage of this important Ivvermectin story. It is good to know that there is courage and integrity still. There are so many moving parts to this story it is difficult to know where to begin but for many a good place to start is the interview with Texas Cardiologist Dr Peter McCullogh. A long interview but a lot of questions are addressed in this important document. Hopefully it is not taken down ( banned on youtube) but you can watch on VIMEO and RUMBLE. here is the vimeo link
    https://vimeo.com/553518199

  3. According to David Robert Grimes in the Scientific American of 26.4.21, we who stand behind this ivermectin study are described thus:
    “ Ineffective treatments ranging from hydrochloroquine to ivermectin to vitamin D and alternative medicine have thrived too, endorsed by a rogues’ gallery of doctors and researchers.”

  4. Hooray! Let’s share this good news to as many people we know as possible. Thank you very much to Dr. Tess Lawrie and all the researchers/investigators for your tireless effort in making IVM known to people. The world is watching, and is waking up. May the truths prevail.

  5. Incredible that there is an Irish Doctor involved in that study and there has not been ONE MENTION of it on our airwaves or our media. This censorship is incredible and must be stopped.